“Novo Nordisk dominates the market”
The specialist in anti-obesity therapies is buzzing: the Danish company Novo Nordisk is highly valued among investors.
On Monday, Novo Nordisk surpassed the French luxury goods manufacturer LVMH as the most valuable European company.
Only Novo Nordisk has so far managed to launch new effective drugs against obesity: Saxenda and Wegovy are the only two novel drugs currently approved for the treatment of obesity in the US.
Whether Novo Nordisk will be able to meet the enormous expectations, however, is by no means certain.
Even with obesity therapies, there are limits to how much money can be made.
The market value of Novo Nordisk reached almost 3 trillion Danish kroner on Tuesday, which is just about 390 billion.
